Certified by Founder
Lodge
MapLight Therapeutics, Inc.
start up
United States
- Palo Alto, CA
- 31/10/2023
- Series C
- $225,000,000
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
- Industry Biotechnology Research
- Website https://maplightrx.com/
- LinkedIn https://www.linkedin.com/company/maplight-therapeutics-inc/about/
Trillium Renewable Chemicals | $13,000,000 | (May 7, 2026)
RadixArk | $100,000,000 | (May 7, 2026)
Astrada | $3,800,000 | (May 7, 2026)
XCaliber Health | $6,500,000 | (May 7, 2026)
Cytospire Therapeutics Ltd | $82,984,705 | (May 7, 2026)
QuantWare | $178,775,560 | (May 7, 2026)
MOSH | $13,000,000 | (May 7, 2026)
InstaSwitch | $4,700,000 | (May 7, 2026)
Smartness | $55,270,590 | (May 7, 2026)
Scout Space | $18,000,000 | (May 7, 2026)
Altara | $7,000,000 | (May 7, 2026)
District | $14,700,000 | (May 7, 2026)